Physician Knowledge of the Benefits, Risks, and Contraindications of Tissue Plasminogen Activator for Acute Ischemic Stroke
2001; Lippincott Williams & Wilkins; Volume: 32; Issue: 9 Linguagem: Inglês
10.1161/str.32.9.2208-b
ISSN1524-4628
AutoresJosé G. Merino, Brian Silver, Edward Wong, Bart M. Demaerschalk, Arturo Tamayo, Vladimir Hachinski,
Tópico(s)Peripheral Artery Disease Management
ResumoHomeStrokeVol. 32, No. 9Physician Knowledge of the Benefits, Risks, and Contraindications of Tissue Plasminogen Activator for Acute Ischemic Stroke Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBPhysician Knowledge of the Benefits, Risks, and Contraindications of Tissue Plasminogen Activator for Acute Ischemic Stroke José G. Merino, MD, Brian Silver, MD, Edward Wong, MD, Bart Demaerschalk, MD, Arturo Tamayo, MD and Vladimir Hachinski, MD José G. MerinoJosé G. Merino Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada , Brian SilverBrian Silver Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada , Edward WongEdward Wong Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada , Bart DemaerschalkBart Demaerschalk Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada , Arturo TamayoArturo Tamayo Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada and Vladimir HachinskiVladimir Hachinski Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada Originally published7 Apr 2018https://doi.org/10.1161/str.32.9.2208-bStroke. 2001;32:2208–2209To the Editor:Emergency room (ER) physicians and neurologists are critical in ensuring a prompt evaluation of patients arriving at the ER within 3 hours of symptom onset and in initiating therapy with tPA. Suboptimal institutional readiness for evaluating patients with acute stroke and fear about the hemorrhagic complications among neurologists are some of the factors that can limit the widespread use of tPA, as reported by Katzan et al.1 Family physicians play an important role in educating patients at risk for stroke about the warning signs of stroke and the importance of contacting 911 as soon as these appear. Limited knowledge about the benefits and an unjustified fear of the side effects may limit stroke patients' access to this treatment. To assess physician knowledge about tPA, we carried out a survey among family physicians, ER physicians, and neurologists in London, Ontario, 1 year after the Health Protection Branch approved the use of tPA for acute ischemic stroke.2Based on Dillman's total design method,3 a survey was mailed to all family physicians (n=266), neurologists (n=19), and ER physicians (n=20) practicing in London, Ontario, in early January 2000. A second mailing was sent in February to those who had not responded. The lists of family doctors and neurologists were obtained from the departments of Family Medicine and Clinical Neurological Sciences at the University of Western Ontario. ER physicians were identified from the faculty directory. The survey consisted of 10 multiple-choice questions. Knowledge of contraindications was evaluated by presenting a brief clinical scenario and asking respondents if the use of tPA was contraindicated in that situation. Respondents had an option of answering "don't know/uncertain" to each question. The percentage of correct responses for each question, sorted by specialty, was calculated.The overall response rate was 57% (147 family physicians, 14 neurologists, and 14 ER physicians responded). Because the answers of neurologists and ER physicians were similar, they were analyzed as a single group. The Table presents the percentage of correct responses to each question sorted by specialty. When the family medicine group was divided in terms of number of years in practice ( 10 [n=120]) the percentage of correct answers was not different (data not shown). The perceived benefit of tPA was similar between both groups; 79% of family doctors (95% CI 73 to 86) and 82% of neurologists and ER physicians (95% CI 68 to 96) agreed that tPA was beneficial for the treatment of acute ischemic stroke. Knowledge of Benefits, Risks, and Contraindications of tPA for Acute Ischemic StrokeGeneral Practitioners (n=147)Emergency Physicians and Neurologists (n=28)Percentage95% ClPercentage95% Cl*Not all conditions listed are contraindications to tPA. Knowledge of contraindications was evaluated by presenting a brief clinical scenario and asking respondents whether the use of tPA was contraindicated in that situation.Approval of tPA for use in acute stroke5446–638978–100Magnitude of beneficial effect105–15110–22Time window4133–497963–94Rate of symptomatic ICH127–183921–57Rate of fatal ICH2115–283921–57Mechanism of action7366–809383–100Knowledge of contraindications* Use of antiplatelets4133–498268–96 Use of anticoagulants4032–486851–85 Prior stroke3830–466447–82 Glucose levels1711–234628–65 Acute high blood pressure3628–444628–65 Seizure at onset2720–342912–45 Rapid improvement2518–327559–91 Age5446–636851–85 Peptic ulcer disease5446–627155–88 Symptoms on awakening1912–256851–85Regardless of specialty, physician awareness about the benefits, risks, indications, and contraindications of tPA for acute stroke is insufficient. Limited knowledge of the benefits and unjustified fear of the side effects may limit stroke patients' access to this treatment. For tPA to be widely used, coordinated efforts by multidisciplinary teams focusing on patient education, rapid access to emergency care, and prompt evaluation in the ER are essential.4 These steps will take place only if physicians are fully aware of the risks and benefits of available treatments. Acute stroke teams should consider the education of their peers an integral part of their mission. Educational efforts should be specialty driven: family physicians need to know about the time constraints, benefits, and risks associated with the use of tPA; ER physicians and neurologists need to be familiar with the indications and contraindications of this therapeutic tool.The Heart and Stroke Foundation of Ontario helped defray the costs of postage. We would like to thank Ms Eva Newhouse and Ms Rebecca Nott for their secretarial assistance.Review of this letter was directed by Graeme J. Hankey, MD.1 Katzan IL, Sila CA, Furlan AJ. Community use of intravenous tissue plasminogen activator for acute stroke: results of the Brain Matters Stroke Management Survey. Stroke. 2001; 32: 861–865.CrossrefMedlineGoogle Scholar2 Norris J, Buchan AM, Cote R, Hachinski V, Phillips SJ, Shuaib A, Silver F, Simard D, Teal P. Canadian guidelines for intravenous thrombolytic treatment with acute ischemic stroke: a consensus statement of the Canadian Stroke Consortium. Can J Neurol Sci. 1998; 25: 257–259.CrossrefMedlineGoogle Scholar3 Dillman DA. Mail and Telephone Surveys: The Total Design Method. New York, NY: John Wiley & Sons; 1978.Google Scholar4 Albers MJ, Hademenos G, Latchaw RE, Jagoda A; Marler JR; Mayberg MR; Starke RD; Todd HW; Viste KM; Girgus M; Shephard T; Emr M; Shwayder P; Walker MD. Recommendations for the establishment of primary stroke centers. JAMA. 2000; 283: 3102–3109.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kuster G, Dutra L, Brasil I, Pacheco E, Arruda M, Volcov C and Domingues R (2016) Performance of four ischemic stroke prognostic scores in a Brazilian population, Arquivos de Neuro-Psiquiatria, 10.1590/0004-282X20160002, 74:2, (133-137), Online publication date: 1-Feb-2016. Saposnik G and Johnston S (2014) Decision Making in Acute Stroke Care, Stroke, 45:7, (2144-2150), Online publication date: 1-Jul-2014.Saposnik G, Reeves M, Johnston S, Bath P and Ovbiagele B (2013) Predicting Clinical Outcomes After Thrombolysis Using the iScore, Stroke, 44:10, (2755-2759), Online publication date: 1-Oct-2013. Saposnik G, Demchuk A, Tu J and Johnston S (2013) The iScore Predicts Efficacy and Risk of Bleeding in the National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Stroke Trial, Journal of Stroke and Cerebrovascular Diseases, 10.1016/j.jstrokecerebrovasdis.2012.09.001, 22:6, (876-882), Online publication date: 1-Aug-2013. Saposnik G, Fang J, Kapral M, Tu J, Mamdani M, Austin P and Johnston S (2012) The iScore Predicts Effectiveness of Thrombolytic Therapy for Acute Ischemic Stroke, Stroke, 43:5, (1315-1322), Online publication date: 1-May-2012. Koennecke H (2014) Systemic thrombolytic therapy of acute ischemic stroke with rtPA, Expert Review of Neurotherapeutics, 10.1586/14737175.2.2.187, 2:2, (187-201), Online publication date: 1-Mar-2002. September 2001Vol 32, Issue 9 Advertisement Article InformationMetrics https://doi.org/10.1161/str.32.9.2208-bPMID: 11546923 Originally publishedApril 7, 2018 PDF download Advertisement
Referência(s)